-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Prescription Opioid Trends in the United States
Measuring and understanding progress in the opioid crisis
Dec 16, 2020
About the Report
The opioid epidemic has captivated the country for a decade, although it lost attention this year in the face of the COVID-19 pandemic, which affected the life and healthcare of patients with chronic pain and addiction and so many others. The impact of COVID-19 on use of prescription opioids has been modest, with use largely rebounding to baseline levels since June. Still, another year of double-digit declines in prescription opioid use in 2020 is expected to further reduce use in the United States to levels not seen since the early 2000s. While the human toll of the opioid epidemic is being addressed differently across the country, efforts in managing prescription opioids and in supporting medication-assisted treatment are showing measurable progress in many states.Report Summary
This report provides a timely view of levels of, and trends in, opioid prescribing, how those vary by state, and how those variations illustrate progress and remaining risks. Prescription opioid volume is expected to drop for the ninth consecutive year — a decline of 60% from its peak in 2011. Per capita use of prescription opioids is expected to drop back to levels of use seen in the early 2000, with the greatest reductions in prescription opioid use – as measured in morphine milligram equivalents (MME) – seen in higher-risk segments taking more than 90 MMEs (per day. The greatest declines in prescription opioid use are seen in states which previously had the highest per capita use.There has been further progress in reducing the highest-risk prescriptions and co-prescribing of opioids with anxiety drugs called benzodiazepines, which are linked to a higher risk of overdose and death. However, the decline in use of co-prescribed opioids and benzodiazepines has been lesser in patients over 65 than in younger patients. While combined prescribing of opioids and benzodiazepines is down by 30% since 2016, the number of seniors estimated to be receiving a combination regimen remains substantial at 1.2 million seniors.
There are sometimes no other alternatives to opioids for pain management, and current drugs for opioid use disorders are themselves narcotics, driving an intense research effort for alternatives, with only limited progress emerging. Treating underlying diseases with symptomatic pain and developing non-opioid therapies is the focus of the current pipeline. Unmet needs in addiction additionally are being addressed with ongoing research on new mechanisms of action and digital therapeutics.
Key Findings
Total national prescription opioid use has declined to 60% of the peak volume in 2011 after another year of double digit decline expected in 2020
- Per capita use of prescription opioids is expected to drop back to levels of use seen in the early 2000.
- Since 2011, total opioid prescriptions have declined by 40%, with declines of 51% and 63% in commercial and cash pay types.
Trends in use of prescription opioids and medication-assisted treatment quickly returned to pre-pandemic levels after initial disruptions
- During the COVID-19 pandemic, as many as 44% fewer patients started new opioid therapy while MAT was less impacted.
- Total opioid prescribing declined 16% at the peak of shutdowns in late April, with significant variations across key specialties.
- Healthcare providers have prescribed longer opioid prescriptions to mitigate COVID-19 disruptions.
- Trends in use of prescription opioids and medication-assisted treatment quickly returned to pre-pandemic levels after initial disruptions.
There is a significant cluster of states with both opioid and MAT use above the national average
- Use of medication-assisted treatment, which was disrupted in 2020 due to COVID-19, remains highly variable across states.
- In 2019, opioid MME per capita declined in every state compared to 2018, with the national average declining by 15%.
- The greatest declines in prescription opioid use are seen in states which previously had the highest per capita use.
Co-prescribing benzodiazepines and opioids — consistently identified as increasing the risk of abuse and/or death — has declined in recent years, but still occurs in more than 1 million patients over the age of 65
- Opioid and benzodiazepine treatments have declined less in patients over 65 than in younger patients.
- About 1.2 million Americans over the age of 65 are estimated to be receiving a combination regimen and therefore at an increased risk of abuse and/or death.
- This number has declined from about 1.7 million in 2016, a lower rate of decline than seen in under 65 year-olds.
- A total of about 18 million seniors are using prescription opioids, benzodiazepines, or a combination, representing about 30% of the 59.4 million total Americans receiving these medicines.